On April 12, 2018 Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, reported that its nonclinical translational data will be presented in two posters at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Chicago, Illinois from April 14-18, 2018 (Press release, Jounce Therapeutics, APR 12, 2018, View Source;p=RssLanding&cat=news&id=2342263 [SID1234525282]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The data presented at AACR (Free AACR Whitepaper) for gastric cancer and triple negative breast cancer provides an example of the way in which we use the Jounce Translational Science Platform to interrogate the cellular microenvironment within the tumor to explore potential biomarkers. These data, focused on our ICOS agonist antibody program, JTX-2011, help inform our clinical development strategy," said Deborah Law, D. Phil., chief scientific officer of Jounce Therapeutics.
Details on the posters are as follows:
Genomics based studies of gastric tumors identify ICOS as potential target for therapeutic intervention
Session Title: Immune Checkpoints 1
Location: McCormick Place South, Exhibit Hall A, Poster Section 31
Date and Time: Monday Apr 16, 2018 from 8:00 AM – 12:00 PM CT
Poster Board Number: 10; Permanent Abstract Number: 1685
Integrated genomics and histology based studies of triple negative breast cancer identify ICOS as potential target for therapeutic intervention
Session Title: Immune Checkpoints 1
Location: McCormick Place South, Exhibit Hall A, Poster Section 31
Date and Time: Monday Apr 16, 2018 from 8:00 AM – 12:00 PM CT
Poster Board Number: 3; Permanent Abstract Number: 1678
The posters will be available on the "Investors and Media" section of the Jounce Therapeutics website at www.jouncetx.com.
About JTX-2011
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells. Preclinical data support that JTX-2011 may have a dual mechanism of action that stimulates anti-tumor T effector cells, and also reduces the immunosuppressive T regulatory cells in the tumor microenvironment. The company is developing JTX-2011 to treat solid tumors as a single agent and in combination with other therapies.